Search results for: Jørgen Vestbo

Items from 1 to 20 out of 105 results

article

Treatable traits in the NOVELTY study

Alvar Agustí, Eleni Rapsomaniki, Richard Beasley, Rod Hughes, more

Background and objective Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent and complex diseases that require personalized management. Although a strategy based on treatable traits (TTs) has been proposed, the prevalence and relationship of TTs to the diagnostic label and disease severity established by the attending physician in a real‐world setting are unknown. We assessed...

article

The need for clean air: The way air pollution and climate change affect allergic rhinitis and asthma

Ibon Eguiluz‐Gracia, Alexander G. Mathioudakis, Sabine Bartel, Susanne J. H. Vijverberg, more

Allergy > 75 > 9 > 2170 - 2184

Air pollution and climate change have a significant impact on human health and well‐being and contribute to the onset and aggravation of allergic rhinitis and asthma among other chronic respiratory diseases. In Westernized countries, households have experienced a process of increasing insulation and individuals tend to spend most of their time indoors. These sequelae implicate a high exposure to indoor...

article

Obstructive sleep apnea and hypertriglyceridaemia share common genetic background: Results of a twin study

Martina Meszaros, Adam Domonkos Tarnoki, David Laszlo Tarnoki, Daniel Tamas Kovacs, more

Journal of Sleep Research > 29 > 4 > n/a - n/a

Obstructive sleep apnea is associated with an increased risk of hypertension, diabetes and dyslipidaemia. Both obstructive sleep apnea and its comorbidities are at least partly heritable, suggesting a common genetic background. Our aim was to analyse the heritability of the relationship between obstructive sleep apnea and its comorbidities using a twin study. Forty‐seven monozygotic and 22 dizygotic...

article

Type IV collagen turnover is predictive of mortality in COPD: a comparison to fibrinogen in a prospective analysis of the ECLIPSE cohort

Sarah Rank Rønnow, Jannie Marie Bülow Sand, Lasse Løcke Langholm, Tina Manon-Jensen, more

Respiratory Research > 2019 > 20 > 1 > 1-10

Background Identifying subjects with chronic obstructive pulmonary disease (COPD) at high risk of exacerbation and mortality is key to aid individual management of COPD. The only FDA approved blood-based drug development biomarker for patients at high risk of mortality, is plasma fibrinogen. In this study, we benchmarked two biomarkers of basement membrane remodeling, a characteristic of COPD, against...

article

Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease

Philip D. Adamson, Julie A. Anderson, Robert D. Brook, Peter M.A. Calverley, more

Journal of the American College of Cardiology > 2018 > 72 > 10 > 1126-1137

Patients with chronic obstructive pulmonary disease (COPD) have increased risk of cardiovascular events.This study evaluated the association between high-sensitivity cardiac troponin I concentration and cardiovascular events in patients with COPD and heightened cardiovascular risk.In a double-blind randomized controlled trial, 16,485 patients with COPD and cardiovascular disease or risk factors were...

article

Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study

Henrik Svedsater, Rupert Jones, Nick Bosanquet, Loretta Jacques, more

Respiratory Medicine > 2018 > 141 > C > 198-206

The Asthma Salford Lung Study demonstrated the effectiveness and safety of initiating once-daily inhaled fluticasone furoate/vilanterol (FF/VI) versus continuing usual care (UC) in asthma patients in UK primary care [1]. Here, we report a detailed analysis of patient-reported outcome (PRO) endpoints.Adults with symptomatic asthma maintained on inhaled corticosteroids (ICS) ± long-acting beta₂-agonists...

article

Left ventricular volume and wall stress are linked to lung function impairment in COPD

Peter Alter, Rudolf A. Jörres, Henrik Watz, Tobias Welte, more

International Journal of Cardiology > 2018 > 261 > C > 172-178

Cardiovascular comorbidities are common in chronic obstructive pulmonary disease (COPD). We examined the association between airflow limitation, hyperinflation and the left ventricle (LV).Patients from the COPD cohort COSYCONET underwent evaluations including forced expiratory volume in 1 s (FEV₁), forced vital capacity (FVC), effective airway resistance (R_eff), intrathoracic gas volume (ITGV), and...

article

Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease

Jeong H. Yun, Andrew Lamb, Robert Chase, Dave Singh, more

Journal of Allergy and Clinical Immunology > 2018 > 141 > 6 > 2037-2047.e10

Eosinophilic airway inflammation in patients with chronic obstructive pulmonary disease (COPD) is associated with exacerbations and responsivity to steroids, suggesting potential shared mechanisms with eosinophilic asthma. However, there is no consistent blood eosinophil count that has been used to define the increased exacerbation risk.We sought to investigate blood eosinophil counts associated with...

article

Biomarkers of collagen turnover are related to annual change in FEV₁ in patients with chronic obstructive pulmonary disease within the ECLIPSE study

Diana J. Leeming, Inger Byrjalsen, Jannie M. B. Sand, Asger R. Bihlet, more

BMC Pulmonary Medicine > 2017 > 17 > 1 > 1-10

Background Change in forced expiratory volume in one second (FEV₁) is important for defining severity of chronic obstructive pulmonary disease (COPD). Serological neoepitope markers of collagen turnover may predict rate of change in FEV₁. Methods One thousand COPD subjects from the observational, multicentre, three-year ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate...

article

Management of Dyspnea and Anxiety in Chronic Obstructive Pulmonary Disease: A Critical Review

Abebaw Mengistu Yohannes, Maira Junkes-Cunha, Jacky Smith, Jorgen Vestbo

Journal of the American Medical Directors Association > 2017 > 18 > 12 > 1096.e1-1096.e17

Anxiety and dyspnea, 2 major symptoms in patients with chronic obstructive pulmonary disease (COPD), are associated with high morbidity and mortality. Thus, critically evaluating and synthesizing the existing literature employing pulmonary rehabilitation (PR) and other behavioral therapies in the treatment of anxiety and dyspnea in patients with COPD may help clinicians determine the most efficacious...

article

Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial

Ashley Woodcock, Jørgen Vestbo, Nawar Diar Bakerly, John New, more

The Lancet > 2017 > 390 > 10109 > 2247-2255

Evidence for management of asthma comes from closely monitored efficacy trials done in highly selected patient groups. There is a need for randomised trials that are closer to usual clinical practice. We did an open-label, randomised, controlled, two-arm effectiveness trial at 74 general practice clinics in Salford and South Manchester, UK. Patients aged 18 years or older with a general practitioner's...

article

The Association of Depressive Symptoms With Rates of Acute Exacerbations in Patients With COPD: Results From a 3-year Longitudinal Follow-up of the ECLIPSE Cohort

Abebaw Mengistu Yohannes, Hana Mülerová, Kim Lavoie, Jorgen Vestbo, more

Journal of the American Medical Directors Association > 2017 > 18 > 11 > 955-959.e6

Depression increases disability and health care utilization in older patients with chronic obstructive pulmonary disease (COPD).To determine contribution of depressive symptoms to the incidence of moderate-severe and severe acute exacerbations of COPD (AECOPD) over 3 years.We analyzed data collected from a prospective cohort of patients with COPD (Evaluation of COPD Longitudinally to Identify Predictive...

article

Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial

Courtney Crim, Peter M.A. Calverley, Julie A. Anderson, Andrew P. Holmes, more

Respiratory Medicine > 2017 > 131 > C > 27-34

Pneumonia risk with inhaled corticosteroid use in chronic obstructive pulmonary disease (COPD) has not been thoroughly assessed in patients with moderate airflow limitation.To determine the incidence of pneumonia and risk factors in COPD patients with moderate airflow limitation who had, or were at high risk for cardiovascular disease.In the Study to Understand Mortality and MorbidITy in COPD (SUMMIT),...

article

Susceptibility to exacerbation in COPD

John R Hurst, Antonio Anzueto, Jørgen Vestbo

The Lancet Respiratory Medicine > 2017 > 5 > 9 > e29

article

A multi-center randomized, controlled, open-label trial evaluating the effects of eosinophil-guided corticosteroid-sparing therapy in hospitalised patients with COPD exacerbations – The CORTICO steroid reduction in COPD (CORTICO-COP) study protocol

Pradeesh Sivapalan, Mia Moberg, Josefin Eklöf, Julie Janner, more

BMC Pulmonary Medicine > 2017 > 17 > 1 > 1-7

Background The most commonly applied treatment for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) is a 5-day course of high-dose systemic corticosteroids. However, this treatment has not been shown to reduce mortality and can potentially have serious side effects.Recent research has shown that, presumably, only a subgroup of COPD patients identifieable by blood eosinophil count...

article

The TRINITY study: Twitter discussion from a respirology journal club – Authors' reply

Jørgen Vestbo

The Lancet Respiratory Medicine > 2017 > 5 > 7 > e26

article

U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics

Diane Lefaudeux, Bertrand De Meulder, Matthew J. Loza, Nancy Peffer, more

Journal of Allergy and Clinical Immunology > 2017 > 139 > 6 > 1797-1807

Asthma is a heterogeneous disease in which there is a differential response to asthma treatments. This heterogeneity needs to be evaluated so that a personalized management approach can be provided.We stratified patients with moderate-to-severe asthma based on clinicophysiologic parameters and performed an omics analysis of sputum.Partition-around-medoids clustering was applied to a training set of...

article

Clinical trial research in focus: time to reflect on the design of exacerbation trials in COPD

Jørgen Vestbo, Ashley Woodcock

The Lancet Respiratory Medicine > 2017 > 5 > 6 > 466-468

article

Abstracts from the 3rd International Severe Asthma Forum (ISAF)

M. E. Ketelaar, K. De Kant, F. N. Dijk, E. M. M. Klaassen, more

Clinical and Translational Allergy > 2017 > 7 > 2 > 1-17

article

Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial

Jørgen Vestbo, Alberto Papi, Massimo Corradi, Viktor Blazhko, more

The Lancet > 2017 > 389 > 10082 > 1919-1929

Limited data are available for the efficacy of triple therapy with two long-acting bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease (COPD). We compared treatment with extrafine beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (BDP/FF/GB; fixed triple) with tiotropium, and BDP/FF plus tiotropium (open triple). For this double-blind,...

Publication date

Last 3 years (1)

Close

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

From:

To:
Set your own date range

Content availability

Available (102)
None (3)

Publication type

article (104)
book (1)

INFONA - science communication portal

Search results for: Jørgen Vestbo

Treatable traits in the NOVELTY study

The need for clean air: The way air pollution and climate change affect allergic rhinitis and asthma

Obstructive sleep apnea and hypertriglyceridaemia share common genetic background: Results of a twin study

Type IV collagen turnover is predictive of mortality in COPD: a comparison to fibrinogen in a prospective analysis of the ECLIPSE cohort

Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease

Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study

Left ventricular volume and wall stress are linked to lung function impairment in COPD

Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease

Biomarkers of collagen turnover are related to annual change in FEV₁ in patients with chronic obstructive pulmonary disease within the ECLIPSE study

Management of Dyspnea and Anxiety in Chronic Obstructive Pulmonary Disease: A Critical Review

Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial

The Association of Depressive Symptoms With Rates of Acute Exacerbations in Patients With COPD: Results From a 3-year Longitudinal Follow-up of the ECLIPSE Cohort

Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial

Susceptibility to exacerbation in COPD

A multi-center randomized, controlled, open-label trial evaluating the effects of eosinophil-guided corticosteroid-sparing therapy in hospitalised patients with COPD exacerbations – The CORTICO steroid reduction in COPD (CORTICO-COP) study protocol

The TRINITY study: Twitter discussion from a respirology journal club – Authors' reply

U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics

Clinical trial research in focus: time to reflect on the design of exacerbation trials in COPD

Abstracts from the 3rd International Severe Asthma Forum (ISAF)

Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial

Filter options

Publication date

Content availability

Publication type

Keywords

Data set

Journal

INFONA - science communication portal

Search results for: Jørgen Vestbo

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Content availability

Publication type

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options